Moderna, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRNA research report →
Companywww.modernatx.com
Moderna, Inc. , a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- CEO
- Stéphane Bancel
- IPO
- 2018
- Employees
- 5,800
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $19.26B
- P/E
- -6.02
- P/S
- 8.67
- P/B
- 2.59
- EV/EBITDA
- -6.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -13.89%
- Op Margin
- -153.35%
- Net Margin
- -143.55%
- ROE
- -36.73%
- ROIC
- -37.32%
Growth & Income
- Revenue
- $1.94B · -39.23%
- Net Income
- $-2,822,000,000 · 20.75%
- EPS
- $-7.26 · 21.68%
- Op Income
- $-3,074,000,000
- FCF YoY
- 49.08%
Performance & Tape
- 52W High
- $59.55
- 52W Low
- $22.28
- 50D MA
- $51.07
- 200D MA
- $36.75
- Beta
- 1.06
- Avg Volume
- 7.77M
Get TickerSpark's AI analysis on MRNA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Hoge Stephen | other | 16,110 |
| May 15, 26 | Hoge Stephen | other | 37,226 |
| May 15, 26 | Hoge Stephen | sell | 53,336 |
| May 15, 26 | Hoge Stephen | other | 37,226 |
| May 15, 26 | Hoge Stephen | other | 16,110 |
| May 6, 26 | Rubenstein David M. | other | 9,681 |
| May 6, 26 | Rubenstein David M. | other | 2,092 |
| May 6, 26 | Hussain Abbas | other | 8,371 |
| May 6, 26 | Horning Sandra | other | 9,681 |
| May 6, 26 | Horning Sandra | other | 2,092 |
Our MRNA Coverage
We haven't published any research on MRNA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MRNA Report →